

(301) 402-0220; Email: [tarak@mail.nih.gov](mailto:tarak@mail.nih.gov). A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization.

**SUPPLEMENTARY INFORMATION:** This technology relates to the use of glucagon-like peptide-1 (GLP-1), exendin-4, and analogs for the treatment of neurodegenerative diseases. These peptides are GLP-1 receptor agonists and incretin mimetics, and enhance glucose-dependent insulin secretion and regulate glucagon secretion. As such, they have been used in the treatment of type 2 diabetes. The inventors have shown that these peptides also exert neurotrophic and neuroprotective effects in a variety of predictive models of neurodegeneration, and thus may represent potential therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), peripheral neuropathy (associated or unassociated with diabetes) and stroke.

The prospective Exclusive Patent License may be granted unless the NIH receives written evidence and argument, within thirty (30) days from the date of this published notice, that establishes that the grant of the contemplated license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the Exclusive Patent License. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2013.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2013-20945 Filed 8-27-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel Detection of Pathogen Induced Cancer.

*Date:* October 1, 2013.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W034, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Adriana Stoica, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20850, 240-276-6368, [Stoicaa2@mail.nih.gov](mailto:Stoicaa2@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel Planning for a National Center for Particle Beam Radiation Therapy Research.

*Date:* October 3, 2013.

*Time:* 9:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 6W032, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892-9750, 240-276-6386, [twinters@mail.nih.gov](mailto:twinters@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel Informatics Technology for Cancer Research.

*Date:* October 22, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites-Hotel, 6711 Democracy Blvd., Bethesda, MD 20817.

*Contact Person:* Viatcheslav A Soldatenkov, MD, Ph.D., Scientific Review

Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W254, Bethesda, MD 20892-8329, 240-276-6378, [soldatenkovv@mail.nih.gov](mailto:soldatenkovv@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel NCI Omnibus Grants on Cancer Genetics and Etiology.

*Date:* October 22-23, 2013.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites Alexandria—Old Town, 1900 Diagonal Road, Alexandria, VA 22314.

*Contact Person:* Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892-8329, 240-276-6369, [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

*Name of Committee:* National Cancer Institute Initial Review Group Subcommittee F—Institutional Training and Education.

*Date:* October 28-29, 2013.

*Time:* 7:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202.

*Contact Person:* Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240-276-6464, [meekert@mail.nih.gov](mailto:meekert@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel Research Answers to NCI's Provocative Questions—Group A (R01).

*Date:* October 31–November 1, 2013.

*Time:* 7:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Clifford W Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Bethesda, MD 20892-9750, 240-276-6378, [schweinfestcw@mail.nih.gov](mailto:schweinfestcw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel Collaborative Human Tissue Network (CHTN) (UM1).

*Date:* November 4-5, 2013.

*Time:* 1:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room: Nov 4-6W030 & Nov 5-7W030, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Donald L Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH,

9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-6382, [donald.coppock@nih.gov](mailto:donald.coppock@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel Small Grants Program for Cancer Epidemiology (R03).

*Date:* November 7, 2013.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Joyce C. Pegues, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, MD 20850, 240-276-6375, [peguesj@mail.nih.gov](mailto:peguesj@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel NCI Experimental Therapeutics—Clinical Trials Network with Phase 1 Emphasis.

*Date:* November 12, 2013.

*Time:* 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute, Shady Grove 9609 Medical Center Drive, Room TE408-410, Rockville, MD 20850, (Telephone Conference Call).

*Contact Person:* Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20850, 240-276-6464, [meekert@mail.nih.gov](mailto:meekert@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/irg/irg.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 22, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-20944 Filed 8-27-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF THE INTERIOR

### Fish and Wildlife Service

[FWS-R1-ES-2013-N105;  
FXES11130100000C2-134-FF01E00000]

#### Endangered and Threatened Wildlife and Plants; Recovery Plan for *Phyllostegia hispida*; Addendum to the Molokai Plant Cluster Recovery Plan

**AGENCY:** Fish and Wildlife Service, Interior.

**ACTION:** Notice of document availability.

**SUMMARY:** We, the U.S. Fish and Wildlife Service, announce the availability of our final recovery plan for *Phyllostegia hispida* (no common name) under the Endangered Species Act of 1973, as amended (Act). This plant species is endemic to the island of Molokai, Hawaii. This plan is an addendum to the recovery plan for the Molokai Plant Cluster, published in September of 1996. The plan includes recovery objectives and criteria, and specific recovery actions necessary to achieve downlisting and delisting of the species and its removal from the Federal List of Endangered and Threatened Wildlife and Plants.

**ADDRESSES:** An electronic copy of the recovery plan is available at <http://www.fws.gov/endangered/species/recovery-plans.html> and <http://www.fws.gov/pacific/ecoservices/endangered/recovery/plans.html>. Copies of the recovery plan are also available by request from the U.S. Fish and Wildlife Service, Pacific Islands Fish and Wildlife Office, 300 Ala Moana Boulevard, Room 3-122, Box 50088, Honolulu, HI 96850 (telephone: 808-792-9400).

**FOR FURTHER INFORMATION CONTACT:** Kristi Young, Deputy Field Supervisor, at the above Honolulu address.

#### SUPPLEMENTARY INFORMATION:

##### Background

Recovery of endangered or threatened animals and plants is a primary goal of the Endangered Species Act (Act) (16 U.S.C. 1531 *et seq.*) and our endangered species program. Recovery means improvement of the status of listed species to the point at which listing is no longer required under the criteria set out in section 4(a)(1) of the Act. Recovery plans describe actions considered necessary for the conservation of listed species, establish criteria for downlisting or delisting, and estimate time and cost for implementing the measures needed for recovery.

The Act requires the development of recovery plans for endangered or

threatened species, unless such a plan would not promote the conservation of the species. Section 4(f) of the Act requires that public notice, and an opportunity for public review and comment, be provided during recovery plan development. The draft recovery plan for *Phyllostegia hispida* was published on June 2, 2011, and was available for public comment through August 1, 2011 (76 FR 31973). We have considered information we received from public comments and peer reviewers in our preparation of the final recovery plan, and have summarized that information in an appendix of the approved recovery plan. We welcome continuing public comment on this recovery plan, and we will consider all substantive comments on an ongoing basis to inform the implementation of recovery activities and future updates to the recovery plan.

We listed *Phyllostegia hispida* under the Act as an endangered species without critical habitat on March 17, 2009 (74 FR 11319). *Phyllostegia hispida* is found only on the island of Molokai. Currently there are less than 10 wild mature individuals, 3 wild seedlings, and approximately 7 to 10 reintroduced individuals on the island of Molokai. No known population is entirely protected from the numerous factors threatening the species' recovery, and the species is endangered throughout its range. *P. hispida* is typically found in wet *Metrosideros polymorpha* (ohia)—dominated forest, occurring between 1,112 and 1,280 meters (3,650 and 4,200 feet) elevation.

The major threats to all known populations are habitat degradation by feral pigs (*Sus scrofa*); habitat degradation by and competition with invasive introduced plants; predation or herbivory by rats (*Rattus* spp.) and nonnative slugs; climate change; habitat degradation by landslides and flooding; and the negative demographic and genetic consequences of extremely small population size, as well as the consequent vulnerability to extinction through deterministic or stochastic (chance) events. Native caterpillar species may also pose an herbivory threat to this species.

The short-term recovery objectives for *Phyllostegia hispida* focus on stabilizing all existing populations. To be considered stable, the species must be managed to control threats (e.g., feral ungulates and invasive plants) and be represented in an *ex situ* population (such as a nursery or arboretum). The long-term objectives leading to downlisting and delisting are an increase in populations and their numbers. This increase may require